Rituximab in Pretreated Elderly or Unfit B-CLL Patients: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Rituximab in Pretreated Elderly or Unfit B-CLL Patients (NCT01576588), a na phase 2 study. The primary outcome is Overall Response Rate.

2. Clinical Question

This is a question about observed response within a treated group, not a direct estimate of how the regimen compares with another treatment. Without a reported primary endpoint result, the registry record cannot show how many participants met the response definition or how precisely the response rate was estimated. It also does not report a population-specific response breakdown, so the record does not establish whether response differed by participant characteristics. The outcomes listed beyond response include progression-free survival, overall survival, and adverse events, but results for those outcomes are not reported in the registry record.

3. Trial Design

This was a phase 2, single-group trial of rituximab added to a glucocorticoid in pretreated elderly or unfit patients with B-CLL. The registry record lists enrollment of 25 and a completed status. The start is recorded as 2011-10 and primary completion as 2016-01. These dates describe the registry record; they do not establish how long any individual participant was followed.

The single listed arm is R-HDMP. Rituximab infusions were scheduled on Day 1, 2, and 3 in cycle 1, and on Day 1 in cycles 2 to 4. Glucocorticoid infusions, either dexamethasone or methyl-prednisolone, were scheduled on Days 1 to 3 in cycles 1-4(6), before the rituximab infusion. The record does not say which glucocorticoid was selected for each participant, whether all participants received the same number of cycles, or whether treatment was modified or discontinued for particular participants.

Masking is recorded as none, so the registry describes no masking. Allocation is recorded as NA, and the trial model is single group. There is therefore no listed parallel control arm against which to interpret response, survival, or adverse-event counts. The design is suited to describing outcomes in the treated group, but by itself does not separate treatment effects from other explanations for observed outcomes, such as the natural course of disease or participant selection.

The primary endpoint was overall response rate, evaluated 3 months +/- 2 weeks after the last treatment cycle. Secondary outcomes listed in the registry are progression-free survival, number of participants with adverse events, and overall survival. Although the record lists four outcome measures, detailed results for the primary endpoint and those secondary outcomes are not reported in the registry record. A protocol-level statistical analysis plan, including any prespecified analysis populations or interim analyses, is not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Overall Response Rate, measured over 3 months +/- 2 weeks after the last treatment cycle..

The primary endpoint, overall response rate (ORR), is a binary response outcome: each participant either meets the response definition or does not. The registry defines response according to iwCLL 2008 guidelines. Qualifying outcomes are complete response (CR), CR with minimal residual disease (MRD) negativity, described as complete molecular remission, nodular partial remission (nPR), and partial response (PR). The planned assessment time was 3 months +/- 2 weeks after the last treatment cycle.

ORR is used in clinical research to describe the proportion of a treated group reaching a specified level of response at a defined assessment. Its value depends on the response criteria, assessment timing, and availability of evaluable assessments. Here, the categories are specified, but the number of participants meeting them, the denominator used for the calculation, and any uncertainty interval are not reported in the registry record. Therefore, the endpoint definition can be described, but the observed ORR cannot be interpreted from this record.

Even when reported, a response proportion in a single group describes outcomes among treated participants; it is not by itself a comparative estimate of benefit. It does not establish how outcomes would have differed under another treatment or no treatment. The registry record also does not report the component counts for CR, MRD-negative CR, nPR, and PR, so it does not permit examination of how the overall response category was composed.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical interpretation starts with the design, the endpoint, and the available results. In this record, the design is single group, the primary outcome is a binary response classification, and the registry does not report the observed primary outcome or a formal analysis. The distinction between what was planned, what was defined, and what was observed is essential: an endpoint definition is not itself an outcome result.

What does a binary endpoint represent?

A binary endpoint classifies each participant into one of two outcome states for a particular analysis, such as meeting or not meeting the response definition. The count meeting the definition can be used to estimate the proportion responding in the analyzed group. That estimate should be interpreted alongside the analysis denominator and an uncertainty interval. The registry record defines which response categories qualify, but does not report the response count, analysis denominator, or interval. It therefore does not permit reconstruction or evaluation of the primary estimate.

For this endpoint, the timing of assessment is part of the definition: response was assessed 3 months +/- 2 weeks after the last treatment cycle. Assessment timing can affect which observations contribute to an endpoint and how results are compared across studies. The record does not report how missing or unevaluable assessments were handled, so it is not possible to determine how the planned assessment window was applied in practice.

Why does the single-group design matter?

A single-group analysis describes outcomes within the group receiving the listed regimen. A comparison of that group with a separate control group would answer a different question, using a contrast between groups. No control group is listed. An outcome observed after treatment cannot, from this design alone, separate the effect of treatment from other influences on the outcome. This is why a response proportion, even if reported, should not be read as a controlled estimate of treatment effect.

Randomization, when part of a comparative trial, aims to make treatment groups comparable on average with respect to measured and unmeasured baseline factors. The registry does not describe a randomized comparison: allocation is NA and the model is single group. There is no basis in this record for interpreting differences against a comparator, because no comparator results are listed.

What does uncertainty quantify?

A confidence interval is a statistical range expressing the uncertainty associated with an estimated quantity under a specified method. For a response proportion, it would help readers judge how much uncertainty remains around the observed estimate. It does not guarantee that the true value lies within a particular interval, nor does it address biases caused by study design, missing data, outcome measurement, or selective reporting. No interval for the primary response outcome is reported in the registry record.

The record's sample-size assumptions describe planning illustrations based on an observed effect, using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. For time-to-event planning, the stated convention is to give the total number of events; for other planning illustrations, it is participants per arm. These assumptions are not a report of the trial's original sample-size justification. They do not turn a single-group trial into a two-arm comparison, and planning sample sizes are not observed power. The registry record does not report a protocol-based sample-size justification.

How should event counts be read?

Adverse-event counts describe participants reported as affected, rather than an estimate of comparative risk. Counts can be informative about what was observed in the treated group, but interpretation depends on how events were defined, collected, and attributed, and on the observation period. The record reports counts at risk and affected for serious and other adverse events, but does not report detailed methods for event collection or attribution. A serious-event term percentage is not the same as a treatment-versus-control effect estimate.

For outcomes involving counts or repeated events, the statistical model must match the data structure. General statistical principle: over-dispersion occurs when observed variability exceeds what a simpler model assumes; ignoring it can make uncertainty estimates too narrow. The registry record does not report a count model or an analysis of over-dispersion, and the primary endpoint is described as participants meeting a response definition rather than a recurrent-event count. No claim about the model used can be made from the record.

What can be concluded when analyses are absent?

The registry lists no analyses. Without a reported analysis, readers cannot check the handling of the analysis population, missing assessments, covariates, or uncertainty. The record does not report whether any adjusted analysis was planned or conducted. General statistical principles can explain why those choices matter, but cannot establish which choices were made in this trial. The endpoint definition and design can be read directly from the record; inferential conclusions require results and methods that are not reported there.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("R-HDMP")
n      <- c(25)
events <- c(7)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  R-HDMP  25  7  28.0  12.1  49.4  14.3  47.6  14.3  47.8

11. Multiplicity, Missing Data and Analysis Populations

Several outcomes are listed: the primary endpoint is overall response rate, and the secondary outcomes are progression-free survival, number of participants with adverse events, and overall survival. The registry record does not report an analysis plan describing how these outcomes were ordered, tested, or interpreted together. It does not report whether any adjustment for multiple comparisons was planned. When researchers examine multiple outcomes or multiple statistical tests, the chance of at least one apparently notable result can increase; multiplicity methods are used in some settings to address that issue. This general concern does not establish that a particular method was used.

The record lists no analyses, and results for the primary and secondary outcomes are not reported in the registry record. It also does not report whether interim analyses occurred, whether stopping rules were specified, or whether an analysis plan was prespecified. These details should not be inferred from the phase, completion status, or endpoint list.

Missing-data handling is not reported in the registry record. In particular, the record does not say how participants without an assessment in the specified response window were treated, whether the primary analysis used all enrolled participants or an evaluable subset, or how incomplete survival follow-up was handled. These choices matter because the analyzed population and assumptions about missing outcomes can affect estimates and their interpretation.

The registry record does not describe intention-to-treat, per-protocol, or safety analysis populations. The enrollment figure alone does not identify the denominator for any specific endpoint analysis. It also does not report exclusions, withdrawals, or reasons for missing assessments. Therefore, the effect of missing data or analysis-population choices cannot be assessed from this record.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: febrile neutropenia (12.0%), neutropenia (8.0%), diarea (8.0%), extrasystolia (4.0%), orfarin overdosage (4.0%).

The registry reports 25 participants at risk for serious adverse events and 9 affected. For other adverse events, it reports 25 at risk and 23 affected. These are counts for the single listed R-HDMP group, not comparisons between treatment arms. The record does not provide a control group or a comparative risk estimate.

Among the serious-event terms listed, febrile neutropenia is recorded as 12.0%, neutropenia as 8.0%, and Diarea as 8.0%. Extrasystolia, Orfarin overdosage, and upper pulmonary infection are each recorded as 4.0%. The terms and spellings follow the registry record. These percentages should be read as registry-reported event figures, not as evidence of a treatment effect or a comparison with another group.

Event categories may not represent mutually exclusive sets of participants: a participant can experience more than one event term. The record does not report the amount of overlap, event timing, recurrence, duration, attribution, or the method used to collect events. It also does not report a death count. Thus, the adverse-event figures describe the listed counts and terms, but cannot provide a full characterization of safety or comparative safety.

13. What the Result Does, and Does Not, Mean

The registry record establishes that a phase 2 single-group study evaluated rituximab in addition to a glucocorticoid in pretreated elderly or unfit patients with B-CLL. It specifies the primary endpoint as overall response rate, defines the response categories by iwCLL 2008 guidance, and gives an assessment window after the final treatment cycle. It also describes the listed regimen and reports adverse-event counts for the R-HDMP group.

The record does not report the primary response count or response rate. It therefore does not show how many participants met the response definition, how precise any response estimate would be, or how response categories contributed to the overall endpoint. Without those results, no conclusion about the observed primary outcome can be drawn from this registry record.

Even if a response estimate were available, the single-group design would limit causal interpretation. There is no listed control group and no randomized comparison. Outcomes in the treated group alone do not establish what would have occurred under a different treatment or without the regimen. The record also does not report results for progression-free survival or overall survival, so those outcomes cannot be assessed from the information recorded.

The adverse-event counts show that the registry recorded participants affected by serious and other adverse events, along with several serious-event terms and percentages. They do not establish whether the regimen caused an event, whether event frequency was higher or lower than under another treatment, or how events varied over time. The absence of detailed event definitions and follow-up information further limits interpretation.

Accordingly, the record is useful for identifying the study question, design, endpoint definition, regimen schedule, and some safety reporting. It is not a complete efficacy or safety results account. The listed enrollment and completion status do not fill the gap left by missing endpoint results, nor do planning assumptions establish observed outcomes or observed power.

14. Why This Trial Matters Statistically

This trial illustrates why study design and outcome reporting must be read together. The registry identifies a clinically defined population and a regimen combining rituximab with a glucocorticoid, then specifies a response endpoint with named criteria and assessment timing. Those details make clear what the primary outcome was intended to measure. But without the observed response result, the endpoint definition cannot answer how participants fared.

Its single-group design is also statistically important. Descriptive outcomes in a treated group can provide information about what was recorded among those participants, but they do not provide a concurrent treatment contrast. Readers should distinguish a group-level response description from evidence that the regimen caused a particular outcome. That distinction applies even when a response endpoint is clinically meaningful.

The registry's safety counts offer a further example of the limits of summary event reporting. Counts and term-specific percentages can identify events recorded in the group, but do not describe comparative safety, participant overlap, timing, or causality. Without detailed methods and results, those dimensions remain unresolved.

Finally, the record shows why statistical transparency matters beyond a single headline estimate. Analysis populations, missing-data methods, uncertainty intervals, multiplicity decisions, and interim-analysis procedures can all affect interpretation. These items are not reported in the registry record. A complete account of outcomes and analysis would be needed to assess precision and robustness. The study is statistically informative as a case in endpoint definition and design limitations, while its registry record leaves the primary efficacy result unreported.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation of the available record is the absence of the primary endpoint result. Although the response definition and assessment window are described, the response count, response proportion, denominator, and uncertainty interval are not reported in the registry record. The endpoint therefore cannot be quantified or evaluated for precision.

The single-group model and lack of a listed comparator limit interpretation of any observed outcome as a treatment effect. Allocation is recorded as NA, masking as none, and no randomized comparison is described. The registry does not report baseline characteristics or subgroup results, so the enrolled population cannot be characterized beyond the stated pretreated elderly or unfit B-CLL population and enrollment figure.

Details needed to interpret endpoint ascertainment are also absent. The registry record does not report how missing or unevaluable response assessments were handled, which analysis population was used, or how withdrawals and incomplete follow-up were addressed. It does not report the statistical analysis plan, a sample-size justification, interim analyses, or methods for multiplicity.

The safety information is limited to counts and selected serious-event terms. The record does not describe event collection, attribution, timing, duration, recurrence, or overlap among affected participants. Results for progression-free survival and overall survival are not reported in the registry record. These gaps prevent a full assessment of outcome completeness and comparative efficacy or safety.

The regimen description permits identification of scheduled infusion timing, but does not establish individual treatment exposure, completion, modifications, or the glucocorticoid selected for each participant. These trial-specific omissions should not be filled by assumptions based on customary practice.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Rituximab in Pretreated Elderly or Unfit B-CLL Patients — NCT01576588.
• Registry record last updated 2019-12-27; status last verified 2019-12.
• Results first posted 2019-12-16.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes NCT01576588, a completed phase 2, single-group study of rituximab plus a glucocorticoid in pretreated elderly or unfit patients with B-CLL. Enrollment is recorded as 25. The start is recorded as 2011-10 and primary completion as 2016-01.

The primary endpoint was overall response rate, defined using iwCLL 2008 response categories and assessed 3 months +/- 2 weeks after the last treatment cycle. The regimen description specifies rituximab and dexamethasone or methyl-prednisolone infusion timing. No comparator group is listed.

Progression-free survival, adverse events, and overall survival are listed as secondary outcomes. The registry reports serious and other adverse-event counts and selected serious-event terms. It does not report the primary response result, survival results, or a statistical analysis. The record therefore documents the study design and endpoint definitions, but does not provide a complete account of efficacy results.